Vaxart (NASDAQ:VXRT) Share Price Passes Below 200 Day Moving Average – Should You Sell?

by · The Markets Daily

Vaxart, Inc. (NASDAQ:VXRT – Get Free Report) passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.78 and traded as low as $0.76. Vaxart shares last traded at $0.78, with a volume of 895,348 shares changing hands.

Analysts Set New Price Targets

Separately, Oppenheimer initiated coverage on Vaxart in a research report on Thursday, August 15th. They issued an “outperform” rating and a $4.00 price target for the company.

Read Our Latest Stock Report on Vaxart

Vaxart Stock Up 5.8 %

The company’s 50 day simple moving average is $0.85 and its 200-day simple moving average is $0.78. The firm has a market cap of $145.59 million, a P/E ratio of -1.55 and a beta of 0.66.

Vaxart (NASDAQ:VXRT – Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.09) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.12). Vaxart had a negative net margin of 543.21% and a negative return on equity of 114.19%. The business had revenue of $6.40 million during the quarter, compared to the consensus estimate of $65.70 million. During the same period last year, the company earned ($0.16) EPS. Equities research analysts predict that Vaxart, Inc. will post -0.47 EPS for the current year.

Institutional Trading of Vaxart

Several institutional investors and hedge funds have recently modified their holdings of the stock. Kingswood Wealth Advisors LLC bought a new stake in Vaxart during the 1st quarter valued at $32,000. Tidal Investments LLC purchased a new stake in Vaxart in the first quarter worth about $56,000. Sequoia Financial Advisors LLC bought a new position in Vaxart during the 2nd quarter worth about $65,000. Monaco Asset Management SAM purchased a new position in Vaxart during the 2nd quarter valued at about $402,000. Finally, Vanguard Group Inc. raised its holdings in shares of Vaxart by 19.9% in the 1st quarter. Vanguard Group Inc. now owns 8,449,362 shares of the biotechnology company’s stock valued at $10,984,000 after purchasing an additional 1,404,391 shares in the last quarter. Institutional investors own 18.05% of the company’s stock.

Vaxart Company Profile

(Get Free Report)

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.

Further Reading